← Leaderboards
Wen Li
University Of California, San Francisco
$1,096,933
Attributed
$3,290,798
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $670.2K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,290,798 · 1
By mechanism
R01$3,290,798 · 1
Top collaborators
- Mark Jesus Magbanua5 shared
- Laura J Van'T Veer5 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Nola M. Hylton$19,153,972
- Alexander Keliimoeanu Smith$10,175,996
- Susan Halabi$7,630,539
- Sei Lee$4,235,785
- Eric J Small$8,436,342
Others in their field
Other Emerging Leaders on “Dna Analysis”
- Leonard Freedman · Leidos Biomedical Research, Inc.$49,483,348
- Lynn Briscoe · Leidos Biomedical Research, Inc.$25,343,101
- Olwen Hahn · Brigham And Women'S Hospital$23,582,395
- Chani Eduard · Precision Bioservices, Inc.$19,909,203
- Ashlin Bolton · Broad Institute, Inc.$19,699,069
- Pradeep Natarajan · Massachusetts General Hospital$11,138,320
Research focus
Dna AnalysisDrug EfficacyAdjuvantDisease-Free SurvivalAdjuvant StudyDistantAdjuvant TherapyBreastAdvanced DiseaseBreast-Conserving SurgeryCancer BurdenCancer SubtypesCharacteristicsBiological MarkersBloodClinical TrialsCohortCompanion DiagnosticsCorrelative StudyBreast Cancer PatientDetectionDiagnosisDiagnostic BiomarkerDrug Evaluation
Grant awards (5)
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$670,225
R01 · FY2025 · CA
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$636,712
R01 · FY2024 · CA
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$656,820
R01 · FY2023 · CA
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$656,818
R01 · FY2022 · CA
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$670,223
R01 · FY2021 · CA